{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:28:23Z","timestamp":1774985303969,"version":"3.50.1"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Chimeric antigen receptor T cells treatment targeting B cell maturation antigen (BCMA) is an emerging treatment option for relapsed\/refractory multiple myeloma (RRMM) and has demonstrated outstanding outcomes in clinical studies.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> The aim of this comprehensive review and meta-analysis was to summarize the effectiveness and safety of anti-BCMA CAR-T treatment for patients with relapsed\/refractory multiple myeloma (RRMM). Our research identifies variables influencing outcome measures to provide additional evidence for CAR-T product updates, clinical trial design, and clinical treatment guidance.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard was followed for conducting this comprehensive review and meta-analysis, which was submitted to PROSPERO (CRD42023390037). From the inception of the study until 10 September 2022, PubMed, Web of Science, EMBASE, the Cochrane Library, CNKI, and WanFang databases were searched for eligible studies. Stata software (version 16.0) was used to assess effectiveness and safety outcomes.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Out of 875 papers, we found 21 relevant trials with 761 patients diagnosed as RRMM and were given anti-BCMA CAR-T treatment. The overall response rate (ORR) for the entire sample was 87% (95% CI: 80\u201393%) complete response rate (CRR) was 44% (95% CI: 34\u201354%). The minimal residual disease (MRD) negativity rate within responders was 78% (95% CI: 65\u201389%). The combined incidence of cytokine release syndrome was 82% (95% CI: 72\u201391%) and neurotoxicity was 10% (95% CI: 5%\u201317%). The median progression-free survival (PFS) was 8.77\u00a0months (95% CI: 7.48\u201310.06), the median overall survival (OS) was 18.87\u00a0months (95% CI: 17.20\u201320.54) and the median duration of response (DOR) was 10.32\u00a0months (95% CI: 9.34\u201311.31).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> According to this meta-analysis, RRMM patients who received anti-BCMA CAR-T treatment have demonstrated both effectiveness and safety. Subgroup analysis confirmed the anticipated inter-study heterogeneity and pinpointed potential factors contributing to safety and efficacy, which may help with the development of CAR-T cell studies and lead to optimized BCMA CAR-T-cell products.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold><jats:ext-link>Clinicaltrials.gov<\/jats:ext-link>, PROSPERO, CRD42023390037.<\/jats:p>","DOI":"10.3389\/fphar.2023.1149138","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T05:44:55Z","timestamp":1687239895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed\/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Dingyuan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diqin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenliang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suping","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaojiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1182\/blood-2020-140410","article-title":"Updated results from the phase I CRB-402 study of anti-bcma CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma: Correlation of expansion and duration of response with T cell phenotypes","volume":"136","author":"Alsina","year":"2020","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1182\/blood.V130.Suppl_1.4413.4413","article-title":"Serum bcma may interfere with anti-bcma-CAR-transduced T cells or other anti-bcma antibody-based immunotherapy in multiple myeloma","volume":"130","author":"Chen","year":"2017","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2020-140727","article-title":"Results from lummicar-1: A phase 1 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in Chinese subjects with relapsed and\/or refractory multiple myeloma","volume":"136","author":"Chen","year":"2020","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1182\/blood-2021-151672","article-title":"Clinical trials of BCMA-targeted CAR-T cells utilizing a novel non-viral transposon system","volume":"138","author":"Costello","year":"2021","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-142695","article-title":"Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM) (PRIME) with novel therapeutic strategies","volume":"136","author":"Costello","year":"2020","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1182\/blood-2018-99-115319","article-title":"Clini-cal predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma","volume":"132","author":"Dancy","year":"2018","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3324\/haematol.2015.137620","article-title":"'Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma","volume":"101","author":"Drent","year":"2016","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/ajh.26583","article-title":"CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status","volume":"97","author":"Du","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood-2021-146678","article-title":"Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma","volume":"138","author":"Duvalyan","year":"2021","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/jco.2021.39.15_suppl.8015","article-title":"Phase 1 study of CART-Ddbcma, a CAR-T therapy utilizing a novel synthetic binding domain for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"2020","author":"Frigault","year":"2020","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/biomedicines9101422","article-title":"'Novel CS1 CAR-T cells and bispecific CS1-BCMA CAR-T cells effectively target multiple myeloma","volume":"9","author":"Golubovskaya","year":"2021","journal-title":"Biomedicines"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-99-117729","article-title":"Fully human bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma","volume":"132","author":"Green","year":"2018","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"839097","DOI":"10.3389\/fimmu.2022.839097","article-title":"Targeting BCMA to treat multiple myeloma: Updates from the 2021 ASH annual meeting","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/s41375-021-01269-3","article-title":"Single VHH-directed BCMA CAR-T cells cause remission of relapsed\/refractory multiple myeloma","volume":"35","author":"Han","year":"2021","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1182\/blood-2020-140156","article-title":"Two-year follow-up of investigator-initiated phase 1 trials of the safety and efficacy of fully human anti-bcma CAR T cells (CT053) in relapsed\/refractory multiple myeloma","volume":"136","author":"Hao","year":"2020","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood-2019-130341","article-title":"Potent anti-tumor activity of bcma CAR-T therapy against heavily treated multiple myeloma and dynamics of immune cell subsets using single-cell mass cytometry","volume":"134","author":"Hu","year":"2019","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"886546","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T cell therapeutics: Evidence, mechanism and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcms.2010.11.001","article-title":"Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias","volume":"39","author":"Knobloch","year":"2011","journal-title":"J. Craniomaxillofac Surg."},{"key":"B30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-139802","article-title":"Results from lummicar-2: A phase 1b\/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and\/or refractory multiple myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat. Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"113919","DOI":"10.1016\/j.biopha.2022.113919","article-title":"Nanobody-based CAR T cells targeting intracellular tumor antigens","volume":"156","author":"Li","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1167\/tvst.9.13.26","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: Updated results from phase 1 CRB-401 study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1038\/bcj.2016.89","article-title":"The role of maintenance therapy in multiple myeloma","volume":"6","author":"Lipe","year":"2016","journal-title":"Blood Cancer J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5562630","DOI":"10.1155\/2021\/5562630","article-title":"'Selective cytotoxicity of single and dual anti-CD19 and anti-cd138 chimeric antigen receptor-natural killer cells against hematologic malignancies","volume":"2021","author":"Luanpitpong","year":"2021","journal-title":"J. Immunol. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: Final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: Initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev."},{"key":"B46","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","article-title":"The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma","volume":"27","author":"Manjunath","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2020.07.002","article-title":"Improving CAR T-cells: The next generation","volume":"57","author":"Marple","year":"2020","journal-title":"Semin. Hematol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol. Cell Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1182\/blood-2021-152688","article-title":"Treatment of patients with T cells expressing a fully-human anti-BCMA CAR with a heavy-chain antigen-recognition domain caused high rates of sustained complete responses and relatively mild toxicity","volume":"138","author":"Mikkilineni","year":"2021","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e004446","DOI":"10.1136\/jitc-2021-004446","article-title":"'Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression","volume":"10","author":"Mueller","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1063838","DOI":"10.3389\/fimmu.2023.1063838","article-title":"T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts","volume":"14","author":"Nasiri","year":"2023","journal-title":"Front. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/leu.2016.211","article-title":"Differentiation stage of myeloma plasma cells: Biological and clinical significance","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e005145","DOI":"10.1136\/jitc-2022-005145","article-title":"Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"10","author":"Qu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"B63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","article-title":"Nanobody-based CAR-T cells for cancer immunotherapy","volume":"10","author":"Safarzadeh Kozani","year":"2022","journal-title":"Biomark. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1158\/1535-7163.MCT-20-1089","article-title":"In like a lamb; out like a lion: Marching CAR T cells toward enhanced efficacy in B-all","volume":"20","author":"Safarzadeh Kozani","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","article-title":"'Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma","volume":"3","author":"Schmidts","year":"2019","journal-title":"Blood Adv."},{"key":"B66","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary disease in multiple myeloma - controversies and future directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev."},{"key":"B67","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"B69","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cells8050472","article-title":"Limitations in the design of chimeric antigen receptors for cancer therapy","volume":"8","author":"Stoiber","year":"2019","journal-title":"Cells"},{"key":"B70","first-page":"381","article-title":"Immunophenotype characteristics in multiple myeloma cells and their significance","volume":"18","author":"Sun","year":"2010","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B71","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B72","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"544754","DOI":"10.3389\/fphar.2020.544754","article-title":"Efficacy and safety of CAR-modified T cell therapy in patients with relapsed or refractory multiple myeloma: A meta-analysis of prospective clinical trials","volume":"11","author":"Xiang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B75","first-page":"466","article-title":"Toxicity management and efficacy evaluation of BCMA-CART in the treatment of relapsed and refractory multiple myeloma","volume":"30","author":"Xiao-Yuan","year":"2022","journal-title":"J. Exp. Hematol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.7150\/ijms.46811","article-title":"Efficacy and safety of CAR-T therapy for relapse or refractory multiple myeloma: A systematic review and meta-analysis","volume":"18","author":"Yang","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1080\/07853890.2021.1970218","article-title":"Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma","volume":"53","author":"Zhang","year":"2021","journal-title":"Ann. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1063986","DOI":"10.3389\/fimmu.2022.1063986","article-title":"'Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory\/relapsed B-cell lymphoma: Case series and review of literature","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: A phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"884782","DOI":"10.3389\/fonc.2022.884782","article-title":"Long-term safety and efficacy of CD19 humanized selective CAR-T therapy in B-all patients who have previously received murine-based CD19 CAR-T therapy","volume":"12","author":"Zhao Y","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1149138\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T05:44:59Z","timestamp":1687239899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1149138\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":80,"alternative-id":["10.3389\/fphar.2023.1149138"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1149138","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"article-number":"1149138"}}